Tesamorelin
FDA approved · RxGrowth-hormone-releasing hormone analog
Also known as: Egrifta
FDA approved and prescription only. Sold as Egrifta for reduction of excess abdominal fat in HIV-associated lipodystrophy (approved 2010).
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 24 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven in human trials: it reduces visceral (deep abdominal) fat in HIV-associated lipodystrophy. It is the only FDA-approved peptide shown to reduce visceral fat. Off-label 'general fat loss' use is not the approved, evidenced indication.
What it is
A stabilised GHRH analog that stimulates growth-hormone release, which in trials reduced visceral fat.
What the research says
Approved on human trial data for this specific indication.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Tesamorelin is the intervention being tested.
Effects of Growth Hormone Releasing Hormone in HIV
Growth Hormone Dynamics and Cardiac Steatosis in HIV
SMART: Somatotrophics, Memory, and Aging Research Trial
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
FDA recalls & enforcement
No FDA recalls are on record for Tesamorelin.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Approved for a specific medical population; broad off-label use is not the evidenced use.
- GH/IGF-1 elevation carries theoretical risks; monitored under prescription.
- Prescription medicine: not for unsupervised use.
Doses reported in studies & protocols
Approved dosing is set by the label and prescriber. This is not a recommendation.
Purity reality
Only pharmacy-dispensed product has a verified supply chain.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.